FACT SHEET
Tumor organoids
Patient-derived models for the next-gen drug discovery and development
Reduce oncology drug attrition rates
Predict patient response before moving your drug to the clinic
HUB Organoids are unique patient-derived in vitro models developed directly from patient biopsies or resections. Our living tumor biobank includes:
- genetically stable organoid models
- a wide range of carcinoma indications
- matched primary tumor and healthy tissue-derived organoids
- organoids derived from both primary and metastatic lesions
Using HUB´s drug screening platform, clinically-relevant data can be generated that allows you to identify new targets, refine your drug combination strategies, or stratify your patient population with confidence.
Download our fact sheet
![patient population patient population](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(4).png)
Identify responders and non-responders
Prospectively identify your target patient population and investigate the mechanism of response in patients.
![drugs drugs](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(5).png)
Test combination strategies
Identify the most promising combo startegy with the only easily scalable patient-derived in vitro system.
![DNA DNA](https://resources.huborganoids.nl/hubfs/graphics%20500x500%20px%20(11).png)
Discover predictive biomarkers
Predict therapeutic outcome using models that recapitulate original patient pathophysiology and preserve patient- and cancer-specific mutations.